

# A randomised controlled trial of pneumococcal conjugate vaccines Synflorix and Prevenar13 in sequence or alone in high-risk Indigenous infants (PREV-IX): immunogenicity, carriage and otitis media outcomes

ACTRN12610000544077

---

<b>Status</b>	RECRUITING
<b>Phase</b>	Phase 3, Phase 4
<b>Sponsor</b>	Menzies School of Health Research
<b>Enrollment</b>	425 participants

## Plain Language Summary

---

This trial is testing different pneumococcal (pneumonia-causing bacteria) vaccines in Indigenous infants who are at high risk of ear infections and pneumonia. Two newer vaccines — Synflorix and Prevenar13 — protect against slightly different bacteria, and researchers want to find out if giving them in sequence or alone works best for Indigenous children, who have higher rates of a specific type of infection.

You may be eligible if:

- Your baby is an Indigenous infant less than 6 weeks of age
- Your baby lives in a remote community
- Your baby is eligible for pneumococcal vaccination

You may NOT be eligible if:

- Your baby was born before 32 weeks of pregnancy (premature birth)

Talk to your doctor about whether this trial might be right for you.

## Key Eligibility Criteria

---

### Inclusion (1)

- Indigenous infants less than 6 weeks of age, living in a remote community and eligible for pneumococcal vaccination.

### Exclusion (1)

- less than 32 weeks gestation

## Locations (1 total)

---

NT,WA, Australia